DiagnaMed Holdings (CSE: DMED) appears to be going all in on artificial intelligence. The drug development firm this morning revealed that it is prioritizing resources to focus solely on CERVAI, its Brain Health Artificial Intelligence Platform.
The platform works to predict and monitor brain age, with the analysis conducted by generative AI providing insights and tools to diagnose, prevent, or improve cognitive decline. The platform is designed to work for both mental health as well as neurodegenerative disorders, and is expected to launch in May 2023 as a general clinical tool.
The CERVAI platform is being developed in conjunction with Drexel University under a license and sponsored research arrangement. It’s development is being lead by Dr John Kounios, Professor of Psychological and Brain Sciences, as well as by Dr Hualou Liang, the latter of whom is focused on incorporating OpenAI’s GPT-3 program into the platform.
READ: DiagnaMed Looks To Obtain Approval For Brain Age Clinical Tool In Q4
GPT-3 will be incorporated as a means of detecting early signs of neurodegenerative disorders, with the program previously demonstrated to be able to identify clues from speech that are as much as 80% accurate in detecting early stages of Alzheimer’s.
“The text embedding, generated by GPT-3, can be reliably used to not only detect individuals with Alzheimer’s Disease from healthy controls, but also infer the subject’s cognitive testing score, both solely based on speech data,” that study concluded.
“By amalgamating our machine learning tools for brain age with EEG recordings, brain health with validated assessment tools, and disease detection with alternative data recordings would make CERVAI™ the world’s first digital health generative AI system for early detection and solution for brain health,” commented CEO Fabio Chianelli.
The first versions of the CERVAI platform are anticipated to be released in May 2023.
DiagnaMed Holdings last traded at $0.055 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
